Search

Displaying results 91 - 100 of 1809 in total
  1. Drug

    Davesomeran

    go.drugbank.com/drugs/DB17091
    ApprovedInvestigational

    of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine. … [L43882] In October 22nd 2022, the FDA approved the Moderna Bivalent Vaccine as a booster in patients 6 years or older, administered at least 2 months after completion of primary vaccination or receipt

  2. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    Latanoprostene Bunod has been used in trials studying the treatment of Glaucoma, Ocular Hypertension, Open-Angle Glaucoma, Open Angle Glaucoma, and Intraocular Pressure. … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma

  3. Drug

    TOL-101

    go.drugbank.com/drugs/DB16980
    Investigational

    Synonyms: Murine IgM monoclonal antibody specific for the human alpha, beta T cell receptor
  4. Drug

    Trastuzumab duocarmazine

    go.drugbank.com/drugs/DB16342
    Investigational

    Trastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).

    Synonyms: Immunoglobulin g1-kappa, anti-(homo sapiens erbb2 (epidermal growth factor receptor 2, receptor tyrosineprotein kinase erbb-2, egfr2, her2, her-2, p185cerbb2, neu, cd340)), humanized monoclonal antibodyCategories: HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
  5. Pathway

    Sphingolipid Signaling (Receptor)

    smpdb.ca/view/SMP0524344
    Signaling

    Through these receptor‑specific G protein couplings—spanning cAMP suppression, Ca²⁺ mobilization, PKC activation, Rho GTPase–driven cytoskeletal remodeling, and PI3K/Akt and MAPK pathways—S1P orchestrates … phosphate (S1P) is a potent bioactive lipid mediator synthesized intracellularly by the phosphorylation of sphingosine by sphingosine kinases SphK1 and SphK2 at the plasma membrane and is then exported via

    Drugs: Nitric Oxide · Calcium · Magnesium cation
    Enzymes: Sphingosine 1-phosphate receptor 2, Sphingosine 1-phosphate receptor 4
  6. Drug

    PBCAR20A

    go.drugbank.com/drugs/DB17189
    Investigational

    Synonyms: Allogeneic gene edited CD20-directed CAR (Chimeric Antigen Receptor) T cells
  7. Drug

    Becotatug

    go.drugbank.com/drugs/DB19069
    Investigational

    JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor

    Synonyms: Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr)), Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-Mus musculus monoclonal JMT101 γ1-chain), disulfide with human-Mus musculus monoclonal JMT101 κ-chain, dimer
  8. Drug

    Cinrebafusp alfa

    go.drugbank.com/drugs/DB18402
    Investigational

    Synonyms: (S228>P,F234>A,L235>A) IMMUNOGLOBULIN G4-KAPPA (CHIMERIC HUMAN-MUS MUSCULUS, ANTI-(RECEPTOR TYROSINE-PROTEIN KINASE ERBB-2, ERBB2, HER2)) FUSED ON BOTH HEAVY CHAINS (1-447, 1''-447'') VIA A (G4S)3 LINKER, IMMUNOGLOBULIN G4 (228-PROLINE, 234-ALANINE, 235-ALANINE), ANTI-(HUMAN TYROSINE KINASE RECEPTOR HER2) (HUMAN-MUS MUSCULUS MONOCLONAL PRS-343 .GAMMA.4-CHAIN) FUSION PROTEIN PEPTIDE (SYNTHETIC 15-AMINO ACID
  9. Drug

    EDI-200

    go.drugbank.com/drugs/DB18188
    Investigational

    EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.

    Synonyms: HUMAN IMMUNOGLOBULIN G1 CONSTANT REGION - HUMAN ECTODYSPLASIN-A1 RECEPTOR-BINDING DOMAIN FUSION PROTEIN
  10. Drug

    Recombinant human alkaline phosphatase

    go.drugbank.com/drugs/DB17672
    Investigational

    Synonyms: recAP